BRPI0206672B8 - composição imunológica, vacina conjugada tetravalente e vacina meningocócica multivalente - Google Patents

composição imunológica, vacina conjugada tetravalente e vacina meningocócica multivalente

Info

Publication number
BRPI0206672B8
BRPI0206672B8 BRPI0206672A BRPI0206672B8 BR PI0206672 B8 BRPI0206672 B8 BR PI0206672B8 BR PI0206672 A BRPI0206672 A BR PI0206672A BR PI0206672 B8 BRPI0206672 B8 BR PI0206672B8
Authority
BR
Brazil
Prior art keywords
vaccine
polysaccharide
protein
multivalent meningococcal
immunological composition
Prior art date
Application number
Other languages
English (en)
Portuguese (pt)
Inventor
P Ryall Robert
Original Assignee
Aventis Pasteur
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23001755&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0206672(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pasteur, Sanofi Pasteur Inc filed Critical Aventis Pasteur
Publication of BR0206672A publication Critical patent/BR0206672A/pt
Publication of BRPI0206672B1 publication Critical patent/BRPI0206672B1/pt
Publication of BRPI0206672B8 publication Critical patent/BRPI0206672B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
BRPI0206672 2001-01-23 2002-01-22 composição imunológica, vacina conjugada tetravalente e vacina meningocócica multivalente BRPI0206672B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26343501P 2001-01-23 2001-01-23
PCT/US2002/001963 WO2002058737A2 (en) 2001-01-23 2002-01-22 Multivalent meningococcal polysaccharide-protein conjugate vaccine

Publications (3)

Publication Number Publication Date
BR0206672A BR0206672A (pt) 2005-05-10
BRPI0206672B1 BRPI0206672B1 (pt) 2018-11-06
BRPI0206672B8 true BRPI0206672B8 (pt) 2021-05-25

Family

ID=23001755

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0206672 BRPI0206672B8 (pt) 2001-01-23 2002-01-22 composição imunológica, vacina conjugada tetravalente e vacina meningocócica multivalente

Country Status (38)

Country Link
US (9) US8722062B2 (enExample)
EP (3) EP1355673B1 (enExample)
JP (6) JP2005504718A (enExample)
KR (2) KR100947757B1 (enExample)
CN (1) CN100556459C (enExample)
AP (1) AP1897A (enExample)
AU (2) AU2007216743A1 (enExample)
BE (3) BE2012C050I2 (enExample)
BR (1) BRPI0206672B8 (enExample)
CA (1) CA2435681C (enExample)
CR (1) CR7035A (enExample)
CY (2) CY1113072T1 (enExample)
DK (2) DK2332581T3 (enExample)
EA (1) EA006947B1 (enExample)
EC (1) ECSP034701A (enExample)
ES (3) ES2892316T3 (enExample)
FR (3) FR12C0072I2 (enExample)
GE (1) GEP20053691B (enExample)
HR (1) HRP20030598B1 (enExample)
HU (2) HU230490B1 (enExample)
IL (3) IL157060A0 (enExample)
IS (1) IS6881A (enExample)
LT (1) LT5177B (enExample)
LU (1) LU92108I2 (enExample)
LV (1) LV13128B (enExample)
MX (2) MXPA03006561A (enExample)
NO (1) NO20033816L (enExample)
NZ (2) NZ602682A (enExample)
OA (1) OA12590A (enExample)
PL (1) PL226184B1 (enExample)
PT (2) PT2332581E (enExample)
RO (1) RO122761B1 (enExample)
SI (1) SI21352A (enExample)
TN (1) TNSN03041A1 (enExample)
UA (1) UA92579C2 (enExample)
WO (1) WO2002058737A2 (enExample)
YU (1) YU66103A (enExample)
ZA (1) ZA200306176B (enExample)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
YU66103A (sh) 2001-01-23 2006-05-25 Aventis Pasteur Vakcina multivalentnog konjugata meningokokalnog polisaharid-proteina
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
AU2014218428B2 (en) * 2001-06-20 2016-08-25 Glaxosmithkline Biologicals Sa Capsular polysaccharide solubilisation and combination vaccines
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
DE60328481D1 (de) * 2002-05-14 2009-09-03 Novartis Vaccines & Diagnostic Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
AU2003299501A1 (en) * 2002-05-16 2004-05-04 Aventis Pasteur, Inc. Animal component free meningococcal polysaccharide fermentation and seedbank development
US20040096461A1 (en) * 2002-07-30 2004-05-20 Baxter Healthcare Corporation Chimeric multivalent polysaccharide conjugate vaccines
WO2004043489A1 (es) * 2002-11-14 2004-05-27 Instituto Finlay. Centro De Investigacion-Produccion De Vacunas Y Sueros. Metodo de obtencion de vacunas conjugadas y composiciones vacunales que las contienen.
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
CN102319427A (zh) * 2003-01-30 2012-01-18 诺华疫苗和诊断有限公司 抗多种脑膜炎球菌血清组的可注射性疫苗
US9296795B2 (en) * 2003-03-07 2016-03-29 Wyeth Holdings, Llc. Polysaccharide-staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
AU2004255526A1 (en) * 2003-05-07 2005-01-20 Aventis Pasteur, Inc. Method of enhanced immunogenicity to meningococcal vaccination
PL1631264T5 (pl) * 2003-06-02 2018-09-28 Glaxosmithkline Biologicals Sa Kompozycje immunogenne oparte na biodegradowalnych mikrocząstkach zawierających toksoid błonicy i tężca
JP2007516181A (ja) * 2003-06-23 2007-06-21 アヴェンティス パストゥール インコーポレイテッド 髄膜炎菌血清群ａおよびｃに対する免疫方法
US20070020293A1 (en) * 2003-06-23 2007-01-25 Michon Francis J Vaccines against group neisseria meningitidis and meningococcal combinations thereof
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
SI1961426T1 (sl) * 2003-10-02 2011-10-28 Novartis Ag Kombinirana cepiva proti meningitisu
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
AU2011204789B2 (en) * 2004-04-22 2013-07-11 Glaxosmithkline Biologicals S.A. Immunising against meningococcal serogroup Y using proteins
GB0408978D0 (en) 2004-04-22 2004-05-26 Chiron Srl Meningococcal fermentation for preparing conjugate vaccines
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
JP5718545B2 (ja) 2004-04-30 2015-05-13 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 髄膜炎菌結合体ワクチン接種
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0413868D0 (en) * 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
EP1784214A4 (en) * 2004-08-30 2009-09-23 Sanofi Pasteur Inc POLYSACCHARIDE / PROTEIN CONJUGATES MULTIVALENT MENINGOCOCCUS DERIVATIVE AND VACCINE
GB0419846D0 (en) 2004-09-07 2004-10-13 Chiron Srl Vaccine adjuvants for saccharides
AU2005286798A1 (en) * 2004-09-21 2006-03-30 Sanofi Pasteur, Inc. Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
WO2006113528A2 (en) 2005-04-18 2006-10-26 Novartis Vaccines And Diagnostics Inc. Expressing hepatitis b virus surface antigen for vaccine preparation
CA2611964C (en) 2005-06-27 2016-11-08 Glaxosmithkline Biologicals S.A. Process for manufacturing vaccines
US8007807B2 (en) 2005-09-01 2011-08-30 Novartis Vaccines And Diagnostics Gmbh Multiple vaccination including serogroup C meningococcus
US20070065462A1 (en) * 2005-09-21 2007-03-22 Ryall Robert P Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
EP1993604B1 (en) * 2006-03-17 2015-12-02 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Methods for preparing complex multivalent immunogenic conjugates
US10543265B2 (en) 2006-03-22 2020-01-28 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
US10828361B2 (en) 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
US8414899B2 (en) 2006-04-11 2013-04-09 Yeda Research And Development Co. Ltd. Vaccines comprising multimeric HSP60 peptide carriers
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
NZ581367A (en) 2007-06-04 2012-05-25 Novartis Ag Formulation of meningitis vaccines containing haemophilus influenzae and neisseria meningitidis
CA2702871A1 (en) 2007-10-19 2009-04-23 Novartis Ag Meningococcal vaccine formulations
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
US20100189737A1 (en) 2008-12-17 2010-07-29 Arico Beatrice Meningococcal vaccines including hemoglobin receptor
US8003112B2 (en) * 2009-04-16 2011-08-23 Howard University Meningococcal and pneumococcal conjugate vaccine and method of using same
ES2707778T3 (es) * 2009-12-30 2019-04-05 Glaxosmithkline Biologicals Sa Inmunógenos polisacáridos conjugados con proteínas portadoras de E. coli
JP2013522287A (ja) 2010-03-18 2013-06-13 ノバルティス アーゲー 血清群ｂ髄膜炎菌のためのアジュバント添加ワクチン
ES2850973T5 (es) 2010-08-23 2024-09-20 Wyeth Llc Formulaciones estables de antígenos rLP2086 de Neisseria meningitidis
US9057716B2 (en) * 2010-09-04 2015-06-16 Novartis Ag Bactericidal antibody assays to assess immunogenicity and potency of meningococcal capsular saccharide vaccines
SG187912A1 (en) 2010-09-10 2013-04-30 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
EP2655389A2 (en) 2010-12-24 2013-10-30 Novartis AG Compounds
US20140112950A1 (en) 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
EP2729178A1 (en) 2011-07-08 2014-05-14 Novartis AG Tyrosine ligation process
CN104080479B (zh) 2011-11-07 2019-11-05 葛兰素史密丝克莱恩生物有限公司 包括spr0096和spr2021抗原的运载体分子
EP2823312B1 (en) 2012-03-08 2019-08-07 GlaxoSmithKline Biologicals SA In vitro potency assay for protein-based meningococcal vaccines
EP2822584A1 (en) 2012-03-08 2015-01-14 Novartis AG Combination vaccines with tlr4 agonists
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
BR112014021658A2 (pt) 2012-03-09 2017-07-11 Pfizer composições de neisseria meningitidis e métodos das mesmas
CN102660602B (zh) * 2012-04-17 2015-03-25 江苏康泰生物医学技术有限公司 快速纯化细菌荚膜多糖的方法
SG10201608675YA (en) 2012-05-22 2016-12-29 Novartis Ag Meningococcus serogroup x conjugate
PT2885007T (pt) * 2012-08-16 2018-12-10 Pfizer Processos e composições de glicoconjugação
JP6324961B2 (ja) 2012-09-06 2018-05-16 ノバルティス アーゲー 血清群ｂ髄膜炎菌とｄ／ｔ／ｐとの組み合わせワクチン
CN102861326A (zh) * 2012-09-19 2013-01-09 天津康希诺生物技术有限公司 流脑多糖-蛋白质缀合疫苗及制备方法
CN105007935A (zh) 2012-12-18 2015-10-28 葛兰素史密丝克莱恩生物有限公司 用于保护免于白喉和/或破伤风的缀合物
EP2964665B1 (en) 2013-03-08 2018-08-01 Pfizer Inc Immunogenic fusion polypeptides
AU2014234408B2 (en) * 2013-03-18 2017-04-20 Glaxosmithkline Biologicals S.A. Method of treatment
KR20160040556A (ko) 2013-07-11 2016-04-14 노파르티스 아게 미생물 트랜스글루타미나제를 사용한 리신-특이적 화학효소적 단백질 변형
EP4098276A1 (en) 2013-09-08 2022-12-07 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US20170198004A1 (en) 2014-05-24 2017-07-13 Biological E Limited Novel semi-synthetic meningococcal conjugate vaccine
KR20190049940A (ko) 2015-02-19 2019-05-09 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
WO2016134275A1 (en) 2015-02-20 2016-08-25 Bayer Healthcare Llc Contrast imaging agent with dissolved gas-evolving fluid
KR20160011136A (ko) 2015-03-25 2016-01-29 한국기계연구원 내식성이 향상된 마그네슘 합금 및 이를 이용하여 제조한 마그네슘 합금 부재의 제조방법
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
WO2017114906A1 (en) 2015-12-30 2017-07-06 Ascendis Pharma A/S Auto injector with cartridge locking system
KR102204927B1 (ko) 2016-07-25 2021-01-19 에스케이바이오사이언스(주) 피막 다당류-단백질 접합 백신의 품질 평가 방법
WO2018042015A1 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
SI3506935T1 (sl) 2016-09-02 2024-06-28 Sanofi Pasteur, Inc. Cepivo proti neisseriji meningitidis
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2019198096A1 (en) * 2018-04-11 2019-10-17 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Tetravalent meningococcal vaccine composition and process to prepare thereof
US12119099B2 (en) 2018-09-12 2024-10-15 Bayer Healthcare Llc System for conducting a fluid injection procedure
EP3632465A1 (en) 2018-10-03 2020-04-08 Sanofi Pasteur Inc. Combined immunization against meningococcal disease and human papillomavirus
WO2020168146A1 (en) * 2019-02-14 2020-08-20 University Of Florida Research Foundation, Inc. Honeybee commensal snodgrassella alvi vaccine against pathogenic neisseriaceae
US12383611B2 (en) 2019-09-27 2025-08-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN110903388B (zh) * 2019-12-03 2024-01-02 兰州生物制品研究所有限责任公司 一种将脑膜炎球菌抗血清去交叉反应的方法
EP3937983B1 (en) 2019-12-17 2025-02-05 9286-3620 Québec Inc. Oral delivery systems based on in situ forming protein/polysaccharide coacervates
KR102610292B1 (ko) 2021-02-10 2023-12-04 에스케이바이오사이언스(주) 스트랩토코커스 뉴모니애 다당류와 운반체 단백질의 접합체 제조 방법
KR20230147075A (ko) 2021-02-19 2023-10-20 사노피 파스퇴르 인크 수막구균 b 재조합 백신
EP4507732A1 (en) 2022-04-11 2025-02-19 Sanofi Pasteur Inc. Protein-saccharide conjugation with sodium cyanoborohydride
TW202423477A (zh) 2022-08-03 2024-06-16 美商賽諾菲巴斯德公司 針對腦膜炎奈瑟氏菌b的含佐劑免疫原性組成物
WO2025034954A1 (en) 2023-08-09 2025-02-13 Bayer Healthcare Llc Noble gas delivery device, cartridge, and triggering system for lung functional and structural imaging

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4351761A (en) 1978-05-15 1982-09-28 Research Corporation Purified antigen to test for Neisseria gonorrhoeae antibodies
US4404371A (en) 1981-01-14 1983-09-13 Battelle Memorial Institute Carboxymethylcellulose with carbonate bridges and preparation thereof
US4351762A (en) * 1981-03-10 1982-09-28 Bioresearch, Inc. Rapid, quantitative peptide synthesis using mixed anhydrides
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4619828A (en) 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
EP0109350B1 (en) 1982-11-10 1991-10-16 Mitsubishi Jukogyo Kabushiki Kaisha Nickel-chromium alloy
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4762713A (en) * 1983-07-05 1988-08-09 The University Of Rochester Boosting of immunogenic conjugate vaccinations by unconjugated bacterial capsular polymers
ATE38064T1 (de) 1985-04-17 1988-11-15 Akzo Nv Verfahren zum anbringen einer wegmarkierungszusammensetzung.
DE3518706A1 (de) 1985-05-24 1986-11-27 Kernforschungszentrum Karlsruhe Gmbh, 7500 Karlsruhe Verfahren zur herstellung von formkoerpern mit verbesserten, isotropen eigenschaften
US4814276A (en) 1986-04-25 1989-03-21 Becton, Dickinson And Company Selective medium for growth of neisseria
ES2070312T5 (es) * 1988-12-19 2003-05-16 American Cyanamid Co Vacuna de proteina de membrana exterior meningococica de clase 1.
US4963534A (en) 1989-05-19 1990-10-16 Merck & Co., Inc. Process for solubilizing polyanoinic bacterial polysaccharides in aprotic solvents
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
DE69231663T2 (de) 1991-03-12 2001-08-23 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharid-protein-konjugate
SK18594A3 (en) 1991-08-16 1994-08-10 Merck & Co Inc Method of production of capsular polysacharide without lipid and endotoxine
US5314811A (en) 1992-07-13 1994-05-24 Merck & Co., Inc. Process for converting lipid-containing bacterial capsular polysaccharide into lipid-free polysaccharide
US5422427A (en) 1991-09-17 1995-06-06 The United States Of America As Represented By The United States Department Of Health And Human Services Pneumococcal fimbrial protein A
FR2682388B1 (fr) 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
JP3626996B2 (ja) * 1992-05-23 2005-03-09 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム Ｂ型肝炎表面抗原および他の抗原からなる複合ワクチン
US5445817A (en) 1992-08-21 1995-08-29 The United States Of America As Represented By The Department Of Health And Human Services Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines
PL175595B1 (pl) * 1992-08-31 1999-01-29 North American Vaccine Inc Antygenowy/immunogenny koniugat do wytwarzania szczepionki przeciwko infekcji N.meningitidis, sposób wytwarzania antygenowego/immunogennego koniugatu oraz szczepionka przeciwko infekcji N.meningitidis
US5811102A (en) * 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
TR199701547T1 (xx) 1995-06-07 1998-03-21 Smithkline Beecham Biologicals S.A. Polisakarit antijen protein e�leni�i i�eren a��.
US20030157129A1 (en) 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
US20020054884A1 (en) 1995-06-23 2002-05-09 Smithkline Beecham Biologicals, Sa Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
DK1082965T3 (da) 1995-06-23 2009-07-27 Glaxosmithkline Biolog Sa Et vaccinepræparat der omfatter et polysaccharidkonjugatantigen adsorberet på aluminiumphosphat
US6248334B1 (en) 1997-01-08 2001-06-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
US6472506B1 (en) * 1997-01-21 2002-10-29 Aventis Pasteur S.A. Polysaccharide-peptide-conjugates
PT975790E (pt) 1997-01-24 2005-01-31 Schweiz Serum & Impfinst Novo metodo para isolar polissacaridos
US6403306B1 (en) * 1997-04-09 2002-06-11 Emory University Serogroup-specific nucleotide sequences in the molecular typing of bacterial isolates and the preparation of vaccines thereto
ES2230687T3 (es) 1997-04-24 2005-05-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Copulacion de proteinas nomodificadas con polisacaridos derivados de haloacilo o de dihaloacilo para la preparacion de vacunas que incluyen proteinas-polisacaridos.
ES2293681T3 (es) 1997-05-28 2008-03-16 Novartis Vaccines And Diagnostics S.R.L. Medio de cultivo con extracto de soja como fuente de aminoacidos pero sin complejos proteinicos de origen animal.
US6413520B1 (en) 1997-06-24 2002-07-02 Chiron Corporation Methods of immunizing adults using anti-meningococcal vaccine compositions
US5965714A (en) 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
CZ302615B6 (cs) 1997-12-23 2011-08-03 Baxter Healthcare S.A. Zpusob cištení kapsulárních polysacharidu od bunecných komponent gramnegativních a grampozitivních bakterií a modifikovaný kapsulární polysacharid
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US6146902A (en) * 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
ATE471328T1 (de) 1999-02-01 2010-07-15 Eisai R&D Man Co Ltd Verbindungen mit immunologischem adjuvanseffekt
DE60043930D1 (de) * 1999-03-19 2010-04-15 Glaxosmithkline Biolog Sa Impfstoff gegen kapsulare polysaccharide von streptococcus pneumoniae
CN100338218C (zh) 1999-05-19 2007-09-19 启龙股份公司 组合式奈瑟球菌组合物
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9925559D0 (en) 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
ATE400296T1 (de) 1999-12-02 2008-07-15 Novartis Vaccines & Diagnostic Zusammensetzungen und methoden zur stabilisierung von biologischen molekülen nach lyophilisierung
US6800455B2 (en) * 2000-03-31 2004-10-05 Scios Inc. Secreted factors
US20030180316A1 (en) 2000-06-29 2003-09-25 Dominique Boutriau Multivalent vaccine composition
YU66103A (sh) * 2001-01-23 2006-05-25 Aventis Pasteur Vakcina multivalentnog konjugata meningokokalnog polisaharid-proteina
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination

Also Published As

Publication number Publication date
EA006947B1 (ru) 2006-06-30
CA2435681A1 (en) 2002-08-01
LU92108I9 (enExample) 2019-01-15
US20130216571A1 (en) 2013-08-22
NO20033816D0 (no) 2003-08-27
PL373710A1 (en) 2005-09-05
ZA200306176B (en) 2005-03-30
CN100556459C (zh) 2009-11-04
MXPA03006561A (es) 2004-10-15
OA12590A (en) 2006-06-08
US20160000928A1 (en) 2016-01-07
PL226184B1 (pl) 2017-06-30
AP1897A (en) 2008-10-10
HRP20030598B1 (hr) 2013-05-31
HUS1600040I1 (hu) 2019-05-28
FR22C1001I2 (fr) 2025-02-07
FR15C0094I2 (fr) 2017-05-19
BE2015C077I2 (enExample) 2021-02-04
US20190060475A1 (en) 2019-02-28
YU66103A (sh) 2006-05-25
BE2012C050I2 (enExample) 2021-03-23
US8722062B2 (en) 2014-05-13
US20030068336A1 (en) 2003-04-10
US9173955B2 (en) 2015-11-03
NO20033816L (no) 2003-09-11
JP2014043475A (ja) 2014-03-13
NZ602682A (en) 2014-05-30
EP2957300A3 (en) 2016-03-30
LU92108I2 (fr) 2013-01-29
KR20090029857A (ko) 2009-03-23
US8999354B2 (en) 2015-04-07
BE2022C502I2 (enExample) 2023-04-12
US20150174259A1 (en) 2015-06-25
AU2007216743A1 (en) 2007-10-04
US10617766B2 (en) 2020-04-14
EP2957300B1 (en) 2021-07-14
US8734813B2 (en) 2014-05-27
JP2005504718A (ja) 2005-02-17
NZ622900A (en) 2015-11-27
SI21352A (sl) 2004-06-30
JP2016128526A (ja) 2016-07-14
KR100947751B1 (ko) 2010-03-18
KR20030084913A (ko) 2003-11-01
JP2014065745A (ja) 2014-04-17
CN1610560A (zh) 2005-04-27
HU230490B1 (hu) 2016-08-29
BR0206672A (pt) 2005-05-10
CY1113072T1 (el) 2015-08-05
EP1355673B1 (en) 2012-05-30
EP2957300A2 (en) 2015-12-23
CY2012030I2 (el) 2016-08-31
FR12C0072I1 (enExample) 2013-01-04
US20130177588A1 (en) 2013-07-11
US20180154010A1 (en) 2018-06-07
IL157060A0 (en) 2004-02-08
PT2332581E (pt) 2015-10-16
GEP20053691B (en) 2005-12-12
WO2002058737A2 (en) 2002-08-01
ES2892316T3 (es) 2022-02-03
JP5795721B2 (ja) 2015-10-14
AP2003002829A0 (en) 2003-09-30
LT5177B (lt) 2004-11-25
UA92579C2 (ru) 2010-11-25
DK1355673T3 (da) 2012-09-17
ES2544979T3 (es) 2015-09-07
FR15C0094I1 (enExample) 2016-01-22
TNSN03041A1 (en) 2005-12-23
IL225522A (en) 2016-04-21
US8741314B2 (en) 2014-06-03
DK2332581T3 (en) 2015-10-05
CY2012030I1 (el) 2015-08-05
US9844601B2 (en) 2017-12-19
IS6881A (is) 2003-07-22
IL225522A0 (en) 2013-06-27
JP2011140522A (ja) 2011-07-21
FR22C1001I1 (fr) 2022-02-18
LT2003071A (en) 2004-08-25
AU2010219288A1 (en) 2010-09-23
RO122761B1 (ro) 2010-01-29
PT1355673E (pt) 2012-08-31
EP1355673A2 (en) 2003-10-29
US20140308311A1 (en) 2014-10-16
EP2332581B1 (en) 2015-07-01
HUP0302999A3 (en) 2011-05-30
BRPI0206672B1 (pt) 2018-11-06
IL157060A (en) 2013-04-30
HUP0302999A2 (hu) 2003-12-29
WO2002058737A3 (en) 2003-05-22
HRP20030598A2 (en) 2005-06-30
CA2435681C (en) 2011-06-21
FR12C0072I2 (fr) 2013-11-01
EP2332581A1 (en) 2011-06-15
LV13128B (en) 2004-07-20
MX341760B (es) 2016-09-02
EA200300827A1 (ru) 2004-06-24
KR100947757B1 (ko) 2010-03-18
US10143757B2 (en) 2018-12-04
ES2388848T3 (es) 2012-10-19
US20130224241A1 (en) 2013-08-29
JP2014043474A (ja) 2014-03-13
ECSP034701A (es) 2003-10-28
CR7035A (es) 2008-11-25

Similar Documents

Publication Publication Date Title
BRPI0206672B8 (pt) composição imunológica, vacina conjugada tetravalente e vacina meningocócica multivalente
Saukkonen et al. Comparative evaluation of potential components for group B meningococcal vaccine by passive protection in the infant rat and in vitro bactericidal assay
EP2364725A3 (en) Immunization method against neisseria meningitidis serogroups a and c
TR201900418T4 (tr) Pnömokok polisakkarit konjugat aşısı.
WO2004103400A3 (en) Multivalent meningococcal derivatized polysaccharide-protein conjugates and corresponding vaccines
AR066376A1 (es) Vacuna
BRPI0721136A8 (pt) conjugado imunogênico, polissacarídeos de streptococcus pneumoniae sorotipo 1, composição imunogênica multivalente e seus métodos de produção
JP2005504718A5 (enExample)
CY1109582T1 (el) Συνδυασμενα μηνιγγοκοκκινα συζευγματα με κοινη πρωτεϊνη φορεα
AR053354A1 (es) Composicion de conjugado polisacarido neumococcico multivalente -proteina
JP2007516219A5 (enExample)
BRPI0516770A (pt) vacina e conjugados de proteìna - derivados de polissacarìdeo de meningocócico multivalente
Makela Conjugate vaccines-a breakthrough in vaccine development
WO2006026689A3 (en) Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
BRPI0516372A (pt) conjugados de polissacarìdeo-proteìna derivatizados meningocócicos multivalentes e vacina
CY1116658T1 (el) Τρι- ή τετραδυναμο εμβολιο προϊοντος συζευξης μηνιγγοκοκκικου πολυσακχαριδιου-crm197
Ali et al. Synergistic Effect of Coadministration of Haemophilus influenzae and Neisseria meningitidis Vaccines on Immune Responses to Meningitis in Mouse Model
TH95746A (th) วัคซีนมัลติวาเลนท์ Streptococcus pneumoniae คอนจูเกต ที่ประกอบรวมด้วย ซีโรไทพ์ 22F แซคคาไรด์ คอนจูเกต

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25C Requirement related to requested transfer of rights

Owner name: AVENTIS PASTEUR (US)

Free format text: A FIM DE ATENDER A ALTERACAO DE NOME REQUERIDA ATRAVES DA PETICAO NO 860140155166, DE 12/09/2014, E NECESSARIO ESCLARECER A DIVERGENCIA ENTRE O NOME DA EMPRESA TITULAR DO PEDIDO E O NOME DA EMPRESA QUE SOFREU ALTERACAO.

B25D Requested change of name of applicant approved

Owner name: SANOFI PASTEUR, INC (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B15G Petition not considered as such [chapter 15.7 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 47/64 (2017.01), A61K 39/095 (2006.01), A61K

Free format text: PROCEDIMENTO AUTOMATICO DE RECLASSIFICACAO. A CLASSIFICACAO IPC ANTERIOR ERA A61K 47/48.

Ipc: A61K 47/64 (2017.01), A61K 39/095 (2006.01), A61K

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: SANOFI PASTEUR, INC (US)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/11/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/01/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 22/01/2022